Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers
Based on this point that some of the cancers do not appropriately respond to conventional therapy and there is the possibility of relapse, immunotherapy is currently under investigation. Cancer immunotherapies are widely recognized as transformational for several cancers and enable to move to the fr...
Guardado en:
Autores principales: | Mehran Bahraini, Alieh Fazeli |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Tehran University of Medical Sciences
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6dcd93027cb0443fad7ae673b4e7770f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
por: Christopher Sloas, et al.
Publicado: (2021) -
Spinoculation and retronectin highly enhance the gene transduction efficiency of Mucin-1-specific chimeric antigen receptor (CAR) in human primary T cells
por: Alireza Rajabzadeh, et al.
Publicado: (2021) -
CAR-T and other adoptive cell therapies for B cell malignancies
por: Peihua Lu, et al.
Publicado: (2021) -
Double Strike Approach for Tumor Attack: Engineering T Cells Using a CD40L:CD28 Chimeric Co-Stimulatory Switch Protein for Enhanced Tumor Targeting in Adoptive Cell Therapy
por: Luis Felipe Olguín-Contreras, et al.
Publicado: (2021) -
CELLULAR IMMUNOTHERAPY: A MODERN APPROACH TO TREATMENT OF ONCOLOGICAL DISEASES
por: Yu. N. Lezhnin, et al.
Publicado: (2018)